eten. Clinical, genetic, and pathological heterogeneity of frontotemporal dementia: a review. Competing Interest: None Declared 2 Word count (abstract, text) : 279, 5904 Number of references : 211 Number of figures, tables : 2,1 Words that cover the main aspects of this article: Frontotemporal dementia, frontotemporal lobar degeneration, tau, TDP-43, FUS, MAPT, Progranulin. Abbreviations FTD, frontotemporal dementia; FTLD, frontotemporal lobar degeneration; MAPT, microtubule associated protein tau; GRN, progranulin; FUS, fused in sarcoma; FTLD-tau, FTLD with tau-positive inclusions; FTLD-TDP, FTLD with TDP-43-positive inclusions; FTLD-FUS, FTLD with FUS positive inclusions. License Statement The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees)he associatio on a worldwide basis Abstract Frontotemporal dementia (FTD) is the second most common young-onset dementia, and is clinically characterized by progressive behavioural change, executive dysfunction and language difficulties. Three clinical syndromes, behavioural variant FTD, semantic dementia and progressive non-fluent aphasia, form part of a clinicopathological spectrum named frontotemporal lobar degeneration (FTLD). The classical neuropsychological phenotype of FTD has been enriched by tests exploring Theory of Mind, social cognition and emotional processing. Imaging studies have detailed the patterns of atrophy associated with different clinical and pathological subtypes. These patterns offer some diagnostic utility while measures of progression of atrophy may be of use in future trials. Between 30-50 percent of FTD is familial and mutations in two genes, MAPT and Progranulin (GRN), account for about half of these cases. Rare defects in VCP, CHMP2B, TARDP and FUS genes have been found in a small number of families. Linkage to chromosome 9p13.2-21.3 has been established in familial FTD with motor neuron disease, although the causative gene is yet to be identified. Recent developments in the immunohistochemistry of FTLD, and also in amyotrophic lateral sclerosis (ALS), have led to a new pathological nomenclature. The two major groups are those with tau-positive inclusions (FTLD-tau) and those with ubiquitin-positive and TDP-43 positive inclusions (FTLD-TDP). Recently a new protein involved in familial ALS, fused in sarcoma (FUS), has been found in FTLD patients with ubiquitin-positive and TDP-43negative inclusions.
Introduction
Frontotemporal dementia (FTD) is the second most common early-onset dementia and is characterized clinically by progressive behavioural changes and frontal executive deficits and/or selective language difficulties. Although recognised over a century ago the last few years have seen rapid advances in our understanding of FTD, its genetic causes and pathological substrates.(1-5) In 1892 Arnold Pick described a patient with progressive aphasia and lobar atrophy, (6) and in 1911 the presence of argyrophilic neuronal inclusions at neuropathological examination, later known as 'Pick bodies', was reported by Alois Alzheimer. (7) The selective involvement of the frontal and/or temporal cortices with relative preservation of more posterior cerebral regions determines the presentation, and gives rise to the terms FTD as a clinical syndrome with distinct subtypes, and the term frontotemporal lobar degeneration (FTLD) to describe the pathological syndrome. The disease progresses from an insidious onset of behavioural change or language impairment and cognitive decline to a severe and more generalised dementia, accompanied by progressive cerebral hypometabolism and atrophy of frontal and temporal lobes preferentially.
The clinical spectrum of FTD encompasses distinct canonical syndromes: the behavioural variant of FTD (bvFTD) and the language variants, semantic dementia (SD) and progressive non-fluent aphasia (PNFA). There is also overlap of FTD with motor neuron disease (FTD-MND or FTD-ALS), as well as the parkinsonian syndromes, progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS). (8) Recent advances in FTD have identified novel genetic defects and a chromosomal locus in hereditary forms of FTLD, (9) (10) (11) (12) (13) (14) as well as novel neuropathological associations, e.g. the proteins TAR DNA binding protein of 43 kDa (TDP-6 43) and fused in sarcoma (FUS) are now recognized in the pathological classification of FTLD. (15) (16) (17) (18) (19) In this review we will discuss the different clinical variants, neuropsychological aspects, neuroimaging, hereditary forms, pathological subtypes and the clinicopathological associations of FTD with the focus on recent developments.
Epidemiology
The exact prevalence of FTD remains uncertain, as there have been only a few studies and these have produced a wide range of estimates. The highest prevalences have been reported from two independent studies in the UK and one Italian study with an estimated prevalence of FTD of 15 -22 per 100,000 inhabitants aged 45 -64 years, (4) (5) 20) which was almost half the prevalence of AD in this age group. (5) However, a study from the Netherlands estimated the prevalence of FTD to be significantly lower (9.4 per 100,000 in the age group of 60 -69 years). (21) The lower prevalence relative to AD in that series is consistent with some pathological series. (22) (23) The estimated prevalence in a Swedish population-based sample of 85-year-olds was 3.1 per 100 inhabitants. (24) Two reported incidence studies of FTD were remarkably consistent; 3.5 and 4.1 cases per 100,000 person-years in the age-group of 45 -64 years. (25) (26) There do not appear to be clear gender differences in susceptibility. (21, 23, (26) (27) The average age at onset is around 50 -60 years, although approximately 10 percent have an age at onset over 70 years (up to 89 years). (9) There is a wide range in durations of illness (2 -20 years) partly reflecting different underlying pathologies. Patients with FTD-MND have the shortest survival with a mean of three years. (9, 28) 
Clinical presentation
BvFTD, SD and PNFA all share an insidious onset and inexorably progressive but variable decline. Each clinical syndrome is associated with topographically distinct cerebral involvement: with bvFTD associated with symmetrical (or right-sided) frontal and anterior temporal dysfunction, PNFA left frontotemporal dysfunction and SD anterior temporal (typically left more than right) deficits. BvFTD is the most common of these subtypes and accounts for about half of all cases (9, 29) without any clear differences in presentation between sporadic and familial bvFTD, or between late and early onset bvFTD.(30) While all of the subtypes can occur in conjunction with motor neuron disease (FTD-MND), it is most commonly seen with bvFTD, occasionally with PNFA and only very rarely with SD.
Emotional blunting, loss of empathy, apathy, selfishness and neglect of personal hygiene are typical of bvFTD, but may be seen in all subtypes. (31) Other frequently reported symptoms are disinhibition, irritability, gluttony, altered preference for foods (particularly for sweets), wandering, pacing, motor and verbal stereotypies, and hoarding.(31) It has been suggested that bvFTD can be subdivided into apathetic and disinhibited variants depending on initial presentation,(32) however these symptoms frequently co-occur and the usefulness of this distinction is questionable.(30) A stereotyped-compulsive syndrome has been recognized as a third variant. (33) A significant correlation with specific topographic patterns of atrophy, hypoperfusion or hypometabolism has been found for several of these symptoms. Apathy is associated with atrophy and dysfunction of the right anterior cingulate cortex and superior frontal gyrus, (34) disinhibition with the right subgenual cingulate cortex and orbitofrontal cortex, (34) (35) (36) overeating with an orbitofrontal-striatal circuit, (37) and executive dysfunction with the dorsolateral and prefrontal cortex. (38) The core features of current clinical criteria for bvFTD encompass an insidious onset and gradually progressive course, early disruption of social and personal conduct, early emotional blunting and lack of insight.(2-3) Stereotypic behaviour, alterations in eating behaviour, and loss of social awareness particularly support a diagnosis of FTD, while more posterior symptoms such as difficulty with spatial orientation and locating objects suggest Alzheimer's disease (AD). (31, (39) (40) Apathy, mood changes, and dysexecutive symptoms occur in both and have not been found to be effective discriminators of FTD from AD. (39, (41) (42) The clinical criteria focus on behavioural changes rather than cognitive disturbances, and therefore might equally apply to a number of psychiatric syndromes, including (late-onset) depression and schizophrenia. However, virtually no studies have focussed on the differentiation of bvFTD from psychiatric disorders. With this in mind, an interesting group of patients is the "non-progressive", "benign" or "slow" bvFTD, who do not (or only slowly) progress over time, and do not show definite structural atrophy or hypometabolism many years from symptom onset. (43) (44) (45) Behavioural symptoms may appear to progress according to carer description but without measurable cognitive change. (45) As these patients with a non-progressive bvFTD appear to have a normal life expectancy and seldom come to autopsy, the underlying pathology is still unknown. PPA subtypes have an association with different types of underlying pathology. SD is associated most commonly with FTLD-TDP type 1 (17) pathology and only rarely with FTLD-tau or AD pathology. (49, (56) (57) PNFA is commonly associated with FTLD-tau, (56, (58) (59) , although AD and to a lesser extent FTLD-TDP pathology have also been described. (49, (57) (58) Finally, LPA is predominantly associated with AD pathology. (58) (59) Although these are relatively strong associations, they are not absolute, and it is currently not possible to predict with certainty the underlying pathology of specific PPA syndromes. 
Neuropsychology and social cognition
Impairment of executive function including planning, organisation, judgement, problem solving and mental flexibility, is characteristic of FTD,(69) whereas memory, visual perception, and spatial skills are usually relatively well-preserved. (50, (70) (71) (72) (73) (74) . However, executive dysfunction may be absent or overshadowed by pronounced behavioural changes in early disease, and may also be seen in AD.(75) Verbal fluency (letter and categorical) is usually impaired in bvFTD and PNFA, but to a lesser degree also in AD. (76) (77) (78) In SD patients, semantic fluency is more impaired than letter fluency. (76, 78) Early episodic memory impairment, a characteristic feature of AD, has also been reported in pathologically-proven bvFTD cases, and in patients with GRN gene mutations. (79) (80) Though orientation in time and place, delayed free recall and delayed recognition are more often impaired in AD than in FTD at initial assessment, it still remains difficult to differentiate FTD from AD in the early phase using standard neuropsychological tests. (81) As standard neuropsychological tests cannot reliably differentiate bvFTD from AD, (82) (83) (84) It will be interesting to investigate further whether impaired social cognition is a very early feature of familial FTD as has already been described in a single case study of a presymptomatic mutation carrier; studying presymptomatic mutation carriers may allow identification of sensitive (even preclinical) cognitive predictors of decline and its neural substrate.(100)
Neuroimaging
Patients with FTD classically have frontal and temporal atrophy and hypometabolism which is often asymmetric. In the clinical setting this is often best seen using volumetric structural MRI scans (with coronal T1 images being particularly useful for assessing asymmetry) or 13 with functional imaging using either FDG-PET or, less commonly, HMPAO-SPECT. More recently, however, neuroimaging studies have aimed to refine these initial findings, mostly in clinical cohorts, but also in pathologically and genetically-confirmed FTD.
Studies of mild bvFTD in clinically-defined cohorts show involvement particularly of frontal and paralimbic areas,(101) namely the anterior cingulate cortex and frontal insula as well as medial frontal and orbitofrontal cortices, hippocampus, striatum and thalamus, more in the right than left hemisphere. With increasing disease severity, more diffuse atrophy in similar areas is seen with involvement of more lateral frontal areas and subsequently more posterior although one small study suggests there may be a difference between patients with MAPT mutations that affect splicing of exon 10 (more medial temporal lobe atrophy) compared with 14 mutations that do not affect splicing of exon 10 (more lateral temporal lobe atrophy). (109) Bringing these findings together, one study that used a cluster analysis to investigate bvFTD suggested there may be four types of bvFTD anatomically: a temporal-dominant subtype associated with MAPT mutations; a temporofrontoparietal subtype that can be associated with GRN mutations but also with other pathologies such as corticobasal degeneration (CBD); as well as frontal-dominant and frontotemporal subtypes. (110) Larger studies of pathologicallyproven patients are needed to confirm these findings.
Early voxel-based morphometry (VBM) studies of SD showed asymmetrical atrophy of the anterior and inferior temporal lobes, (111) (112) usually affecting the left more than the right hemisphere. These findings were supported by subsequent region of interest (R OI) studies of the temporal lobe, which identified involvement particularly of the temporal pole and anterior parts of the entorhinal cortex, fusiform gyrus, inferior temporal gyrus, amygdala and hippocampus with relative sparing of the superior temporal gyrus. (113) (114) Most studies have used clinically-defined cohorts but one study looking at measurement of cortical thickness in patients with left greater than right temporal lobe atrophy showed a similar pattern of involvement in a pathologically-confirmed cohort of patients, all with FTLD-TDP. (115) . This study also showed that areas within the left hemisphere outside the temporal lobe are involved with increasing disease severity, namely orbitofrontal, inferior frontal, insular, and anterior cingulate cortices.(115) Increasing involvement of the temporal lobe in the right hemisphere is seen with disease progression. (115) (116) A mirror-image pattern of initial atrophy and disease progression seems to occur in those with right greater than left temporal lobe involvement (RTLA).(117) Although SD is characteristically FTLD-TDP pathologically, in a small number of cases, Pick's disease (FTLD-tau) and occasionally AD pathology can be seen. One small study showed similar patterns of atrophy in the FTLD-TDP and FTLD-tau but with a qualitatively different pattern in those with AD who had mostly hippocampal involvement, lack of the knife-edge anterior temporal atrophy seen in the other groups and without the sparing of the superior temporal gyrus. (118) Studies of PNFA are fewer and more heterogeneous, which reflects the clinical heterogeneity of this group. As with SD, there is asymmetrical involvement with more atrophy in the left hemisphere and most significant involvement of the inferior frontal lobe and anterior insula. (52, 116, (119) (120) With increasing severity there is involvement of left superior temporal, middle and superior frontal and anterior parietal lobes. (116) ROI studies have also shown involvement of the caudate in PNFA. (121) There are few pathologically-confirmed studies of PNFA and these are usually in mixed pathological groups but they show similar findings to the clinical cohort studies. (116, 122) Some small studies suggest there may be different patterns of atrophy in PNFA patients with PSP clinically (and therefore likely pathologically) compared to those without PSP, (123) and also in those with GRN mutations (FTLD-TDP pathologically) compared to those without.(63) More detailed studies of PNFA subgroups will be needed to confirm these findings. A different neuroimaging tool that accurately differentiates FTLD from AD is arterial spin labeling (ASL) perfusion MRI, which reveals noninvasive quantification of cerebral blood blow, without the use of ionizing radiation as in SPECT or PET. (130) Patients with AD pathologically can also be defined using amyloid molecular imaging (e.g. PIB-PET) (131) but the availability of such scans is currently limited to a few large research centres.
One of the more novel concepts to emerge from recent neuroimaging studies of FTD using the technique of resting-state fMRI is the idea that FTD is caused by degeneration within specific intrinsic functional connectivity networks that are selectively vulnerable to FTLD pathologies.(132) Consistent with earlier VBM findings in structural MRI studies of bvFTD, resting-state fMRI studies show attenuated connectivity within an anterior 'salience' network of dorsal anterior cingulate and frontoinsular cortices which has connectivity to subcortical and limbic structures. (133) In contrast there appears to be enhanced connectivity in the more posterior 'default' network which has been shown to be affected in AD.(133) These findings have been linked to specific neuropathological findings (early involvement of von Economo neurons in FTD), (134) and further work will be needed to look at whether specific pathological subtypes can be linked to specific and distinct neural network degeneration. 
Cerebrospinal fluid and plasma biomarkers

Genetics
A positive family history has been found in 30 -50 percent of patients with bvFTD, whereas patients with SD or PNFA have a much lower frequency. (9-11, 21, 145-146) The heritability in FTD-MND differs between studies from 10 -60 percent. (9, 11, 146) An autosomal dominant mode of inheritance is found in 10 -27 percent of all FTD patients. (9-11, 21, 145-146) .
Genetic heterogeneity of FTLD is reflected by the identification of mutations in the microtubule associated protein tau (MAPT) and progranulin (GRN) genes in approximately 50 percent of the familial cases, whereas mutations in the valosin containing protein (VCP), charged multivesicular body protein 2B (CHMP2B), TAR-DNA binding protein (TARDP), and fused in sarcoma (FUS) genes are found in less than five percent. Familial FTD-MND has been linked to chromosome 9, but the causative gene defect has yet to be discovered. 
MAPT
Genetic risk factors
Several investigators have tried to identify genetic risk factors for FTD. Homozygosity for the T allele of the SNP rs5848 was found to have a 3.2 fold increased risk for developing FTLD-TDP, (194) but this observation could not be replicated in other studies. (195) (196) The same is true for three other SNPs of the GRN gene, which were initially found to be associated with younger onset age or shorter survival in FTLD or ALS. (9, 194) Also, an association of the showed increased TMEM106B expression in the frontal cortex of FTLD-TDP than in controls, suggesting that increased TMEM106B expression in the brain might be linked to mechanisms of disease in FTLD-TDP and that risk alleles at TMEM106B confer genetic susceptibility by increasing gene expression. (203) 
Genetic screening in clinical practice
The benefit of genetic screening in FTD depends on the strength of the family history and the clinical subtype. Genetic defects, either MAPT or GRN, are most often found in patients with an autosomal dominant form of bvFTD. (9, 146) Genetic screening in SD is unlikely to be useful, although patients who develop semantic impairment later in the illness may have a MAPT gene mutation, (9, 146) whereas a GRN mutation can be found in a familial form of PNFA. (9, 146, 156) Current gene defects are very rare in FTD-MND, and genetic screening is therefore likely not to be useful at present. (9, 146) Screening in sporadic patients will be of little value as a very few mutations have been found in sporadic patients, except for those with a concealed or incomplete family history. In this latter group, careful consideration is necessary before embarking on and genetic screening. 
